UB Paderborn / Katalog / Suche / in CDI

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

The New England journal of medicine, 2023-06, Vol.388 (25), p.2338-2348, Article 2338

2023

Volltextzugriff (PDF)

The role of vitamin D in hematologic disease and stem cell transplantation

Nutrients, 2013-06, Vol.5 (6), p.2206-2221

2013

Volltextzugriff (PDF)

Delayed kidney transplantation after HLA-haploidentical hematopoietic cell transplantation in a young woman with myelodysplastic syndrome with renal failure

Leukemia research reports, 2022-01, Vol.17, p.100302, Article 100302

2022

Volltextzugriff (PDF)

Balancing risks and rewards: How hematologists discuss uncertainty in allogeneic hematopoietic cell transplantation outcomes

Patient education and counseling, 2024-06, Vol.123, p.108177-108177, Article 108177

2024

Volltextzugriff (PDF)

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

The Lancet. Haematology, 2023-11, Vol.10 (11), p.e890-e901

2023

Volltextzugriff (PDF)

Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy

American journal of hematology, 2022-09, Vol.97 (9), p.1170-1177

2022

Volltextzugriff (PDF)

New methods for assessing response in acute myeloid leukemia

Current opinion in hematology, 2015-03, Vol.22 (2), p.132-138

2015

Volltextzugriff (PDF)

Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia

Leukemia & lymphoma, 2021-01, Vol.62 (1), p.158-166

2021

Volltextzugriff (PDF)

Communication Strategies of Transplant Hematologists in High-Risk Decision-Making Conversations

JCO oncology practice, 2024-04, Vol.20 (4), p.538

2024

Volltextzugriff (PDF)

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network, 2023-05, Vol.21 (5), p.503

2023

Volltextzugriff (PDF)

A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial

Transplantation and cellular therapy, 2023-06, Vol.29 (6), p.358.e1-358.e7

2023

Volltextzugriff (PDF)

Splenic Lymphomas Presenting as Splenomegaly

Oncology (Williston Park, N.Y.), 2015-06, Vol.29 (6), p.427-441

2015

Volltextzugriff (PDF)

Impact of Early Hospitalization, Medical Comorbidities and Allogeneic Stem Cell Transplantation on Survival in Acute Myeloid Leukemia Patients Treated with Venetoclax Based Therapy - a Single Institution Experience from an Academic Center

Blood, 2022-11, Vol.140 (Supplement 1), p.6099-6101

2022

Volltextzugriff (PDF)

Clinical utilization of the Myeloid Malignancies Mutation Panel

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e18523-e18523

2017

Volltextzugriff (PDF)

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Blood, 2022-11, Vol.140 (Supplement 1), p.4431-4433

2022

Volltextzugriff (PDF)

A Quality Improvement Initiative to Improve Implementation of Guideline-Concordant Hereditary Myeloid Malignancy Syndrome Evaluation

Blood, 2022-11, Vol.140 (Supplement 1), p.10828-10829

2022

Volltextzugriff (PDF)

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.481-481

2021

Volltextzugriff (PDF)

Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.483-483

2021

Volltextzugriff (PDF)

Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Relapsed/Refractory Acute Myeloid Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.5246-5246

2018

Volltextzugriff (PDF)

HemOnc.org: A Collaborative Online Knowledge Platform for Oncology Professionals

Journal of oncology practice, 2015-05, Vol.11 (3), p.e336

2015

Volltextzugriff (PDF)

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Blood, 2019-11, Vol.134 (Supplement_1), p.5470-5470

2019

Volltextzugriff (PDF)

A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies

Blood, 2018-11, Vol.132 (Supplement 1), p.2107-2107

2018

Volltextzugriff (PDF)

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia

Blood, 2019-11, Vol.134 (Supplement_1), p.2036-2036

2019

Volltextzugriff (PDF)

Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)

Blood, 2019-11, Vol.134 (Supplement_1), p.783-783

2019

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

The role of vitamin D in hematologic disease and stem cell transplantation

Delayed kidney transplantation after HLA-haploidentical hematopoietic cell transplantation in a young woman with myelodysplastic syndrome with renal failure

Balancing risks and rewards: How hematologists discuss uncertainty in allogeneic hematopoietic cell transplantation outcomes

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy

New methods for assessing response in acute myeloid leukemia

Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia

Communication Strategies of Transplant Hematologists in High-Risk Decision-Making Conversations

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology

A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial

Splenic Lymphomas Presenting as Splenomegaly

Impact of Early Hospitalization, Medical Comorbidities and Allogeneic Stem Cell Transplantation on Survival in Acute Myeloid Leukemia Patients Treated with Venetoclax Based Therapy - a Single Institution Experience from an Academic Center

Clinical utilization of the Myeloid Malignancies Mutation Panel

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

A Quality Improvement Initiative to Improve Implementation of Guideline-Concordant Hereditary Myeloid Malignancy Syndrome Evaluation

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial

Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy

Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Relapsed/Refractory Acute Myeloid Leukemia

HemOnc.org: A Collaborative Online Knowledge Platform for Oncology Professionals

Lenalidomide and Rituximab Maintenance Therapy after Front-Line Induction Chemoimmunotherapy in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia

Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)

Suchergebnisse filtern